ESTRO 2021 Abstract Book

Symposium Project from A to Z in a hot or new topic Where do you start? And how to publish?. ...............................(abs. 590 - 594) Poster highlights Poster Highlights 22: Dosimetry 2...................................................................................................................(abs. 595 - 601) Poster Highlights 23: CNS 2..............................................................................................................................(abs. 602 - 608) Award lecture K Breur Award....................................................................................................................................................(abs. 609 - 610) Honorary Physicist Award. ...............................................................................................................................(abs. 611 - 612) Proffered papers Proffered papers 35: Adaptive radiotherapy..................................................................................................(abs. 613 - 618) Proffered papers 36: Lower GI.........................................................................................................................(abs. 619 - 624) Proffered papers 37: Immuno and targeted agents......................................................................................(abs. 625 - 630) Proffered papers 38: Treatment planning: applications...............................................................................(abs. 631 - 636) Proffered papers 39: Outcome modelling 2...................................................................................................(abs. 637 - 642) Proffered papers 40: Advances in RT planning..............................................................................................(abs. 643 - 648) Poster highlights Poster Highlights 24: Imaging acquisition and processing............................................................................(abs. 649 - 655) Poster Highlights 25: Prostate..........................................................................................................................(abs. 656 - 662) Teaching Lecture The 4 Rs of radiobiology revisited in hypofractionated radiotherapy.................................................................. (abs. 663) Clinical need vs technology push in innovation...................................................................................................... (abs. 664) Multi-modality treatment of soft tissue sarcoma. .................................................................................................. (abs. 665) Distracting techniques for paediatric/AYA/adult radiotherapy............................................................................. (abs. 666) The medical device regulation and its implications for (your own) medical hard and software........................ (abs. 667) Physics perspective of stereotactic cardiac ablation.............................................................................................. (abs. 668) Health literacy: The cornerstone of the patient’s understanding of radiotherapy.............................................. (abs. 669) Symposium RBE in proton therapy.......................................................................................................................................(abs. 670 - 673) Surface-guided radiotherapy...........................................................................................................................(abs. 674 - 676) Debate Is it primetime for stereotactic radiotherapy for localised high-risk prostate cancer?..............................(abs. 677 - 681) Symposium Radiotherapy in oesophageal cancer..............................................................................................................(abs. 682 - 684) Debate Hype or Hope? This house believes that the application of radiomics will significantly improve clinical outcome of radiotherapy by 2025...........................................................(abs. 685 - 689) Symposium COVID-19: Lessons learned from a medical physics perspective.................................................................(abs. 690 - 694) The use of telehealth in radiotherapy.............................................................................................................(abs. 695 - 697) State-of-the-art in prostate cancer..................................................................................................................(abs. 698 - 700) MR Linacs - Do we really know what are we doing?.......................................................................................(abs. 701 - 703) The evolving role of elective nodal irradiation in 2021 in head and neck, lung, breast and prostate cancer..........................................................................................................................................(abs. 704 - 707) Recent developments in the treatment of rectal cancer...............................................................................(abs. 708 - 711) Proving the clinical benefit of 15 years of IGRT..............................................................................................(abs. 712 - 716) Novel technology for treatment delivery and modulation: Flash, microbeams and spatio-temporal fractionation..................................................................................................................(abs. 717 - 720) The impact of immoblisation/positioning in advanced radiotherapy..........................................................(abs. 721 - 723)

TUESDAY 31 AUGUST 2021